MetLife
MET
$96.64
-0.41%
MetLife, Inc. is one of the largest life insurers in the United States by assets, providing a broad range of life insurance, annuities, employee benefits, and retirement solutions through six reporting segments: Group Benefits, Retirement and Income Solutions (RIS), Asia, Latin America, EMEA, and MetLife Investment Management. The company occupies a dominant position in the U.S. group benefits market and holds leading market positions in Mexico and Chile, with its Asia segment — primarily tied to Japan — representing roughly a quarter of adjusted earnings, giving it a distinctly international earnings base relative to many domestic peers. The current investor narrative centers on MetLife's ability to sustain earnings growth through rising group benefits margins, disciplined capital return via buybacks and dividends, and a favorable interest-rate environment that supports investment income, even as the stock's strong multi-month rally has raised questions about whether the easy money has already been made. Attention is also focused on the company's capital deployment priorities and the durability of its Japan and Latin America franchises amid currency and macro headwinds.…
MET
MetLife
$96.64
Investment Opinion: Should I buy MET Today?
Rating: Hold. MetLife presents a balanced risk/reward profile at current levels, with the analyst consensus 'buy' rating and average target price of $105.06 implying 8.3% upside, but the stock's premium trailing valuation and limited near-term catalysts suggest waiting for a better entry point. The core thesis is that MET is a high-quality, cash-generative insurer with a sustainable dividend and improving margins, but much of the near-term optimism is already priced in after a 41.54% six-month rally. Supporting evidence includes the forward PE of 8.89x, which is attractive if the $13.50 EPS estimate is met, and the robust TTM free cash flow of $16.53 billion that comfortably covers the 3.24% dividend yield and buybacks. Revenue growth of 4.44% year-over-year is modest but positive, and net margin expanded to 6.21% in Q1 2026 from 5.17% a year earlier. The stock's 1.85x price-to-book is above the sector average, but the 0.68x PS ratio and 7.82x EV/EBITDA are reasonable. The biggest risks are the disconnect between GAAP and adjusted earnings, currency exposure in Asia and Latin America, and the potential for multiple compression if growth slows. This Hold would upgrade to Buy if the stock pulls back to the $90–$93 support zone or if forward EPS estimates are revised upward, and it would downgrade to Sell if revenue growth decelerates below 2% or if the forward EPS estimate is cut. Relative to its history, MET is fairly valued to slightly overvalued on trailing metrics, but undervalued on a forward basis if estimates hold.
Sign up to view all
MET 12-Month Price Forecast
MetLife is a high-quality, cash-generative insurer trading at a premium on trailing metrics but a deep discount on forward earnings, creating a binary outcome depending on whether the $13.50 EPS estimate is achieved. The stock's strong relative momentum and low beta make it an attractive defensive holding, but the 41.54% six-month rally has likely priced in much of the near-term optimism. The base case (55% probability) sees the stock trading in the $100–$108 range, aligned with the analyst average target, while the bull case (25%) could push it to $119 if execution exceeds expectations. The bear case (20%) risks a fall to $84 or lower if earnings disappoint or currency headwinds intensify. I would upgrade to bullish if Q2 2026 earnings show EPS above $1.80 and revenue growth accelerating above 5%, and downgrade to bearish if the forward EPS estimate is cut below $12.50 or if the stock breaks below the $93 support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on MetLife's 12-month outlook, with a consensus price target around $105.06 and implied upside of +8.7% versus the current price.
Average Target
$105.06
0 analysts
Implied Upside
+8.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $119
Analyst target range
Coverage on MetLife is robust, with 16 analysts contributing to the consensus. The recommendation distribution leans bullish, with a consensus recommendation of "buy" and a recommendation mean of 1.94 (where 1.0 is a strong buy and 5.0 is a strong sell). The average target price is $105.06, which implies roughly 8.3% upside from the current price of $97.04. Recent institutional ratings show a consistent pattern of reaffirmations rather than upgrades or downgrades: Keefe Bruyette & Woods (Outperform), Evercore ISI (In Line), Jefferies (Buy), Wells Fargo (Overweight), Mizuho (Outperform), UBS (Buy), Barclays (Overweight), and Morgan Stanley (Overweight) all reiterated their positions in July 2026, while Piper Sandler maintained a Neutral stance. The absence of downgrades amid a strong price run is a constructive signal, though the lack of fresh upgrades suggests analysts see the stock as fairly valued near current levels. The target range spans from a low of $84.00 to a high of $119.00, a spread of $35.00, or approximately 36% of the current price — a moderately wide dispersion that signals meaningful disagreement about the earnings trajectory. The high target of $119.00 implies roughly 22.6% upside and likely assumes successful execution on the forward EPS estimate of $13.50, multiple expansion toward 9x–10x forward earnings, and continued capital return; it may also embed a favorable rate environment and strong Asia segment performance. The low target of $84.00 implies about 13.4% downside and likely prices in margin compression, adverse currency translation in Japan and Latin America, or a more conservative view that the trailing GAAP earnings power — not the adjusted forward estimate — is the correct anchor. The consensus revenue estimate of $92.83 billion (range $89.05 billion to $95.01 billion) and EPS estimate of $13.50 (range $12.79 to $13.91) provide the fundamental scaffolding for these targets. With a short ratio of 3.58 days and a beta of 0.759, the stock is not a crowded short and tends to trade with lower volatility than the market, which may limit the speed of any target-price convergence but also reduces the risk of a violent squeeze-driven move.
Bulls vs Bears: MET Investment Factors
The bull case for MetLife rests on its strong relative momentum, deep forward valuation discount, robust cash generation, and improving profitability, supported by a 'buy' consensus and 8.3% upside to the average analyst target. The bear case centers on the stock's premium trailing valuation versus peers, limited near-term upside to resistance, and the critical disconnect between GAAP and adjusted earnings that underpins the forward multiple. Currently, the bull evidence appears stronger, given the company's consistent capital return, margin expansion, and analyst reaffirmations, but the debate hinges on whether the forward EPS estimate of $13.50 is achievable. The single most important tension is the valuation anchor: if the market is correct to price MET on normalized forward earnings, the stock is cheap; if not, the trailing 16.45x PE and 1.85x book value leave little margin for error. This factor, more than any other, will determine whether the stock breaks through $100.93 resistance or retreats toward the $93–$95 support zone.
Bullish
- Strong Relative Momentum Leadership: MET has outperformed the S&P 500 by 24.1 percentage points over the past six months (41.54% vs. 17.44%) and by 11.39 points over three months, demonstrating persistent relative strength even as absolute momentum cools. The stock's 1-month relative strength of +2.99 points versus SPY's -0.96% decline suggests it is attracting defensive flows amid broader market softness.
- Deep Forward Valuation Discount: The forward PE of 8.89x versus a trailing PE of 16.45x implies the market expects a dramatic earnings rebound, with consensus EPS of $13.50 versus trailing GAAP EPS of $0.064 (a data artifact). If the forward estimate is achievable, MET trades at less than 9x earnings, which would be deeply undervalued for a franchise of this quality and scale.
- Robust Cash Generation and Capital Return: MET generated $2.687 billion of operating cash flow and $2.687 billion of free cash flow in Q1 2026 alone, with TTM free cash flow of $16.53 billion. This comfortably covers the $417 million of dividends paid and $755 million of stock repurchased in the quarter, supporting a 3.24% dividend yield with a well-covered 50.4% payout ratio.
- Improving Profitability Trends: Q1 2026 net margin expanded to 6.21% from 5.17% a year earlier, while gross margin rose to 37.24% from 25.85% in Q1 2025. Operating margin also improved to 7.90% from 4.69% in Q4 2025, and EPS grew to $1.75 from $1.29 year-over-year, indicating strengthening underwriting and expense discipline.
Bearish
- Premium Valuation Versus Peers: MET's trailing PE of 16.45x and price-to-book of 1.85x sit at a premium to the broader life insurance sector, where many peers trade between 8x and 12x earnings and 0.8x to 1.2x book. This premium leaves less room for error, especially if the forward EPS estimate of $13.50 proves overly optimistic.
- Limited Near-Term Upside to Resistance: At $97.04, the stock is at approximately 88% of its 52-week range (low $67.33, high $100.93), with key resistance just 4% above at the 52-week high. The 1-month gain of 2.03% and 3-month gain of 13.39% are well below the 6-month pace of 41.54%, indicating decelerating momentum and limited headroom before testing highs.
- Earnings Volatility and GAAP Disconnect: The trailing PE of 16.45x is based on GAAP net income, while the forward PE of 8.89x relies on an adjusted EPS estimate of $13.50 that is vastly higher than trailing GAAP EPS. This disconnect is critical: if the forward estimate is not achieved, the trailing multiple is the more honest anchor, and the stock could be significantly overvalued.
- International and Currency Exposure: The Asia segment, primarily tied to Japan, contributes roughly 25% of adjusted earnings, and Latin America adds around 14%, exposing MET to currency translation and macro headwinds in these regions. Adverse yen or peso movements could pressure earnings and reduce the attractiveness of the dividend when converted to dollars.
MET Technical Analysis
MetLife is in a sustained uptrend, with the shares up 22.73% over the trailing year and 20.82% year-to-date, decisively outperforming the S&P 500's 15.01% and 11.70% respective gains. At a current price of $97.04, the stock sits at approximately 88% of its 52-week range (low of $67.33, high of $100.93), positioning it in the upper quartile of its annual band — a sign of persistent momentum but also of limited near-term headroom before testing the highs. The 6-month gain of 41.54% underscores how forceful this advance has been, and the fact that the stock has not yet reclaimed the $100.93 high suggests a consolidation phase rather than a blow-off top. Recent momentum remains constructive but is decelerating relative to the spring surge: the 1-month change of +2.03% and 3-month change of +13.39% are positive but well below the 6-month pace, indicating the trend is maturing rather than breaking. Notably, MET's 1-month relative strength versus SPY is +2.99 percentage points, and its 3-month relative strength is +11.39 points, meaning the stock is outperforming even as its absolute momentum cools — a healthy sign of leadership. The 1-month gain also contrasts with SPY's -0.96% decline over the same period, suggesting MET is attracting defensive flows amid broader market softness. Key resistance sits at the 52-week high of $100.93, roughly 4% above the current price; a decisive breakout above that level would signal a continuation of the primary uptrend and likely invite momentum-driven buying. Support is anchored at the 52-week low of $67.33, though a more relevant near-term floor lies in the $93–$95 zone, where the stock consolidated in August and early September. With a beta of 0.759, MET is roughly 24% less volatile than the broader market, which supports a lower-risk position sizing profile and helps explain the stock's resilience during SPY's recent pullback; the maximum drawdown of -18.33% over the period further confirms a relatively contained risk profile for an equity of this size.
Beta
0.76
0.76x market volatility
Max Drawdown
-18.3%
Largest decline past year
52-Week Range
$67-$101
Price range past year
Annual Return
+22.1%
Cumulative gain past year
| Period | MET Return | S&P 500 |
|---|---|---|
| 1m | +2.4% | +1.0% |
| 3m | +9.8% | +5.4% |
| 6m | +37.3% | +17.8% |
| 1y | +22.1% | +16.5% |
| ytd | +20.3% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MET Fundamental Analysis
MetLife's revenue trajectory is growing but uneven. The most recent quarter (Q1 2026, ended 2026-03-31) delivered revenue of $19.074 billion, up 4.44% year-over-year from $18.263 billion in Q1 2025, while the prior quarter (Q4 2025) posted $23.814 billion — a sequential jump driven by seasonal and investment-related items. The multi-quarter trend shows revenue oscillating between roughly $16.9 billion and $23.8 billion, reflecting the inherent volatility of insurance premium and investment income recognition rather than a smooth compounding curve. Notably, Q1 2026 revenue of $19.074 billion exceeded Q3 2025's $16.881 billion and Q2 2025's $17.176 billion, suggesting underlying business momentum is intact even if the headline growth rate appears modest. The investment case hinges on whether Group Benefits and RIS — which together contribute roughly 52% of adjusted earnings — can sustain pricing discipline and volume growth as the company laps a favorable rate environment. Profitability is solid but thin in absolute margin terms, as is typical for large life insurers. Q1 2026 net income was $1.185 billion on $19.074 billion of revenue, a net margin of 6.21%, up from 5.17% in Q1 2025 and 3.40% in Q4 2025. Gross margin in Q1 2026 was 37.24%, a meaningful expansion from 30.53% in Q4 2025 and 25.85% in Q1 2025, though the quarterly gross margin series is volatile (Q3 2025 was just 17.40%). Operating margin stood at 7.90% in Q1 2026 versus 4.69% in Q4 2025, and the trailing operating margin of 6.05% reflects the blended run-rate. The company is clearly profitable, with EPS of $1.75 in Q1 2026 versus $1.29 in Q1 2025, and the margin expansion trend — while noisy — supports the narrative of improving underwriting and expense discipline. MetLife's balance sheet and cash generation are its core strengths. The company generated $2.687 billion of operating cash flow and $2.687 billion of free cash flow in Q1 2026 alone, with TTM free cash flow of $16.53 billion, comfortably covering the $417 million of dividends paid and $755 million of stock repurchased in the quarter. The debt-to-equity ratio of 0.711 is moderate for an insurer, and the total-debt-to-capitalization ratio of 42.6% (Q1 2026) is stable versus 41.5% in Q4 2025. ROE of 11.90% (per key metrics) and ROA of just 0.45% reflect the leveraged, spread-based nature of the insurance business model, while the current ratio of 0.65 is low but not unusual for an insurer with large investment portfolios. The dividend yield of 3.24% and payout ratio of 50.4% indicate a shareholder-return policy that is generous but well-covered by earnings and cash flow, and the $22.687 billion cash balance at quarter-end provides substantial liquidity.
Quarterly Revenue
$19.1B
2026-03
Revenue YoY Growth
+4.4%
YoY Comparison
Gross Margin
37.2%
Latest Quarter
Free Cash Flow
$16.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MET Overvalued?
Because MetLife is solidly profitable — Q1 2026 net income of $1.185 billion and trailing EPS of $0.064 (reflecting the low quarterly EPS figure in the key metrics, which appears to be a data artifact) — the PE ratio is the appropriate primary valuation metric. The trailing PE of 16.45x compares to a forward PE of just 8.89x, an unusually wide gap that implies the market expects a dramatic earnings rebound; consensus estimated EPS of $13.50 versus the trailing figure suggests the forward multiple is being calculated on a normalized or adjusted earnings base rather than GAAP net income. This disconnect is critical: if the forward EPS estimate of $13.50 is achievable, MET trades at less than 9x earnings, which would be deeply undervalued for a franchise of this quality; if it is not, the trailing 16.45x is the more honest anchor. On a peer-relative basis, MetLife's 16.45x trailing PE and 1.85x price-to-book sit at a premium to the broader life insurance sector, where many peers trade between 8x and 12x earnings and 0.8x to 1.2x book. The PS ratio of 0.68x and EV/Sales of 1.08x, however, look inexpensive in absolute terms, and the EV/EBITDA of 7.82x is modest. The premium on book value is arguably justified by MetLife's superior scale, diversified earnings mix, and consistent capital return, but the 16.45x trailing PE leaves less room for error than the sector average. Historically, MET's PE has ranged from a low of roughly 3.9x (Q2 2021) to a high of 795x (Q1 2023, distorted by near-zero earnings), with more representative readings in the 10x–20x band over the past three years. The current 16.45x is in the upper half of that normalized range, while the price-to-book of 1.85x is above the 1.4x–1.9x range seen through much of 2023–2024. The dividend yield of 3.24% is notably above the 0.7%–1.0% yields recorded in the historical ratios data, reflecting both the stock's price appreciation and dividend growth. Taken together, the valuation is not stretched on a forward basis but is no longer cheap on trailing metrics, suggesting the market has already priced in a meaningful portion of the earnings recovery story.
PE
16.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.8x
Enterprise Value Multiple
Investment Risk Disclosure
MetLife's financial and operational risks are moderate but manageable. The debt-to-equity ratio of 0.711 and total-debt-to-capitalization of 42.6% are stable for a large insurer, but the current ratio of 0.65 is low, reflecting the leveraged, spread-based nature of the business. Revenue growth is modest at 4.44% year-over-year in Q1 2026, and the quarterly revenue series is volatile, oscillating between $16.9 billion and $23.8 billion, which complicates earnings predictability. Additionally, the company's reliance on Group Benefits and RIS for roughly 52% of adjusted earnings means any pricing pressure or volume slowdown in these segments could disproportionately impact results. The Asia segment, contributing about 25% of earnings, adds currency and regulatory risk, particularly in Japan. Market and competitive risks are significant given MET's premium valuation. The trailing PE of 16.45x and price-to-book of 1.85x are above the life insurance sector's typical 8x–12x earnings and 0.8x–1.2x book, leaving the stock vulnerable to multiple compression if growth disappoints. With a beta of 0.759, MET is less volatile than the market, but this also means it may lag in a strong bull market. Competitive disruption from fintech and alternative asset managers in the annuities and retirement space could pressure margins, while regulatory changes in key markets like Japan and Mexico pose additional headwinds. The lack of recent news makes it difficult to assess emerging threats, but the stock's strong run-up may attract profit-taking. The worst-case scenario would involve a combination of factors: a failure to achieve the forward EPS estimate of $13.50, leading to a re-rating toward the trailing multiple; adverse currency movements in Japan and Latin America; and a broader market correction that compresses valuations across financials. In this scenario, MET could fall to its 52-week low of $67.33, representing a 30.6% decline from the current price of $97.04. The analyst low target of $84.00 implies a 13.4% downside, but a more severe outcome could see the stock test the $67–$70 range if earnings disappoint and the dividend yield fails to attract support. Investors could lose 30% or more in this adverse scenario, though the 3.24% dividend yield and low beta may provide some cushion.
FAQ
The most severe risk is earnings disappointment relative to the forward EPS estimate of $13.50, which could trigger a re-rating toward the trailing PE of 16.45x and a drop to the analyst low target of $84.00 or lower. Financial risks include the modest 4.44% revenue growth and volatile quarterly margins, with gross margin swinging from 17.40% in Q3 2025 to 37.24% in Q1 2026. Competitive and market risks include premium valuation versus peers (1.85x book vs. sector 0.8x–1.2x) and potential multiple compression if interest rates fall or credit losses rise. Company-specific risks include currency exposure in Japan and Latin America, which contribute roughly 39% of adjusted earnings, and regulatory changes in these markets. Ranked by severity: earnings miss, currency headwinds, valuation compression, and regulatory changes.
Our 12-month forecast for MET includes three scenarios: a base case (55% probability) with a target range of $100–$108, aligned with the analyst average target of $105.06, assuming low-single-digit revenue growth and stable margins; a bull case (25% probability) with a target range of $110–$119, driven by successful execution on the $13.50 EPS estimate and a breakout above $100.93 resistance; and a bear case (20% probability) with a target range of $67–$84, if earnings disappoint or currency headwinds intensify. The most likely scenario is the base case, which assumes MET meets consensus expectations and continues its capital return program. The key assumption behind the base case is that net margin holds above 6% and interest rates remain supportive, allowing the company to gradually close the gap between trailing and forward earnings.
MET's valuation is mixed: on a trailing basis, the PE of 16.45x and price-to-book of 1.85x are at a premium to the life insurance sector, where peers trade between 8x–12x earnings and 0.8x–1.2x book. However, on a forward basis, the PE of 8.89x is deeply undervalued if the consensus EPS estimate of $13.50 is achieved. The PS ratio of 0.68x and EV/EBITDA of 7.82x are also reasonable in absolute terms. The market appears to be pricing in a significant earnings rebound, but the wide gap between trailing and forward multiples suggests uncertainty. Relative to its own history, MET's current PE is in the upper half of its normalized 10x–20x range, while the price-to-book is above the 1.4x–1.9x range seen in 2023–2024. Overall, the stock is fairly valued to slightly overvalued on trailing metrics but potentially undervalued on forward estimates.
From a risk/reward perspective, MET is a reasonable buy for income-oriented investors, but the current price of $97.04 offers limited upside to the analyst average target of $105.06 (8.3%). The forward PE of 8.89x is attractive if the $13.50 EPS estimate is met, but the trailing PE of 16.45x and price-to-book of 1.85x are premium to peers. The biggest downside risk is a failure to achieve forward estimates, which could send the stock to the analyst low target of $84.00 (13.4% downside) or the 52-week low of $67.33 (30.6% downside). For long-term investors comfortable with modest growth and a 3.24% dividend yield, MET is a solid holding, especially on pullbacks to the $90–$93 support zone. However, for those seeking high growth, the stock may disappoint given its 4.44% revenue growth and low beta.
MET is better suited for long-term investment, given its low beta of 0.759, stable dividend yield of 3.24%, and consistent capital return through buybacks. The stock's growth stage is mature, with revenue growing at 4.44% year-over-year, and earnings visibility is moderate, supported by a diversified business mix but subject to currency and interest rate fluctuations. Short-term trading is less attractive due to the stock's low volatility and the limited near-term upside to resistance at $100.93, which is only 4% above the current price. A suggested minimum holding period is 2–3 years to fully benefit from dividend compounding and potential multiple expansion if forward earnings estimates are realized. Investors should monitor quarterly earnings and currency trends, but the stock is not suited for quick trades given its defensive characteristics.